Merck Acquires Spero Therapeutics for $277M

Ticker: SPRO · Form: 8-K · Filed: Sep 10, 2024 · CIK: 1701108

Spero Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySpero Therapeutics, Inc. (SPRO)
Form Type8-K
Filed DateSep 10, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentbullish

Sentiment: bullish

Topics: acquisition, biotech, antibiotics, merger

Related Tickers: MRK, SPRO

TL;DR

Merck buying Spero for $277M to fight superbugs. Deal closes Q4.

AI Summary

Spero Therapeutics, Inc. announced on September 9, 2024, that it has entered into a definitive agreement to be acquired by Merck & Co., Inc. for $11.00 per share in cash, totaling approximately $277 million. This acquisition aims to enhance Merck's portfolio of novel antibiotics to combat antimicrobial resistance.

Why It Matters

This acquisition by Merck signifies a significant move to bolster its pipeline against the growing threat of antibiotic-resistant bacteria, potentially impacting the development of new treatments for serious infections.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals, which introduces a degree of uncertainty until completion.

Key Numbers

  • $277 million — Acquisition Value (Total cash consideration for Spero Therapeutics)
  • $11.00 — Per Share Price (Cash amount offered for each Spero Therapeutics share)

Key Players & Entities

  • Spero Therapeutics, Inc. (company) — Registrant
  • Merck & Co., Inc. (company) — Acquiring company
  • $11.00 (dollar_amount) — Per share acquisition price
  • $277 million (dollar_amount) — Total acquisition value
  • September 9, 2024 (date) — Date of definitive agreement

FAQ

What is the primary strategic rationale behind Merck's acquisition of Spero Therapeutics?

Merck is acquiring Spero Therapeutics to enhance its portfolio of novel antibiotics and combat the growing threat of antimicrobial resistance.

What is the total value of the transaction?

The transaction is valued at approximately $277 million.

What is the per-share price for Spero Therapeutics' common stock?

Merck has agreed to pay $11.00 per share in cash for Spero Therapeutics' common stock.

When was the definitive agreement for the acquisition announced?

The definitive agreement was announced on September 9, 2024.

What are the conditions for the closing of the acquisition?

The acquisition is subject to customary closing conditions, including the receipt of regulatory approvals.

Filing Stats: 555 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-09-10 06:56:05

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value SPRO The Nasdaq Global Se

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Corporate Investor Presentation of Spero Therapeutics, Inc. as of September 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 10, 2024 SPERO THERAPEUTICS, INC. By: /s/ Esther Rajavelu Esther Rajavelu Chief Financial Officer and Chief Business Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.